about
Sedation during bronchoscopy: data from a nationwide sedation and monitoring survey.The impact of obstructive sleep apnoea on the aorta.CPAP vs Mandibular Advancement Devices and Blood Pressure in Patients With Obstructive Sleep Apnea: A Systematic Review and Meta-analysis.A multicentre randomised controlled trial and economic evaluation of continuous positive airway pressure for the treatment of obstructive sleep apnoea syndrome in older people: PREDICT.Comparison of the effects of continuous positive airway pressure and mandibular advancement devices on sleepiness in patients with obstructive sleep apnoea: a network meta-analysis.Systemic therapy for vulval Erosive Lichen Planus (the 'hELP' trial): study protocol for a randomised controlled trial.Effect of rituximab on pulmonary function in patients with rheumatoid arthritis.Effect of CPAP on Cardiac Function in Minimally Symptomatic Patients with OSA: Results from a Subset of the MOSAIC Randomized Trial.Simulated Obstructive Sleep Apnea Increases P-Wave Duration and P-Wave Dispersion.The Roles of the Charlson Comorbidity Index and Time to First Antibiotic Dose as Predictors of Outcome in Pneumococcal Community-Acquired Pneumonia.In patients with minimally symptomatic OSA can baseline characteristics and early patterns of CPAP usage predict those who are likely to be longer-term users of CPAPECG risk markers for atrial fibrillation and sudden cardiac death in minimally symptomatic obstructive sleep apnoea: the MOSAIC randomised trial.Prevalence and Risk Factors of Sleep Disordered Breathing in Fabry disease: A Prospective Cohort Study.Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial.Effects of CPAP and Mandibular Advancement Devices on Health-Related Quality of Life in OSA: A Systematic Review and Meta-analysis.Obstructive sleep apnoea and quality of life in Ehlers-Danlos syndrome: a parallel cohort study.Type I error rates of multi-arm multi-stage clinical trials: strong control and impact of intermediate outcomes.Risk of Sleepiness-Related Accidents in Switzerland: Results of an Online Sleep Apnea Risk Questionnaire and Awareness Campaigns.Reducing bias in open-label trials where blinded outcome assessment is not feasible: strategies from two randomised trials.Reappraisal of the clinical effect of mepolizumab - Authors' reply.Comments on 'A modest proposal for dropping poor arms in clinical trials' by Proschan and Dodd.Help for Future Research: Lessons Learned in Trial Design, Recruitment, and Delivery From the "hELP" Study
P50
Q31119835-519159B0-87A2-4309-B3DA-1F23479F96A5Q34482466-A7313E7A-2007-4ADB-85E1-CCAB20256AA8Q34503663-A23FB607-1560-489B-9336-D5EBFA6A9518Q35660642-0F745951-8D94-4A71-ABBD-1F1CF18A2689Q35819605-69CC7643-4E2B-465E-AFA3-C7234D810FA2Q35884757-321E8CCA-F078-46CF-996A-4AA58A4C2D2BQ35921593-7DDF11FB-9794-4442-AA48-CAA8F3D956DCQ35976688-F972569F-88CD-4542-A06D-57A411681F92Q35987401-637CB79C-B70B-4F9E-9A9A-E361C485ACF4Q36074229-E7B8FB98-9DC5-4326-A120-0D8B7A240B0CQ36540088-C54F5385-2322-4AAF-8091-2CE97F0200D9Q36707342-54D980F0-9AA9-4B95-AB5D-4FD9AF3BF7A5Q37624272-9E5566B6-7DEA-43B4-8C33-F10AE4A8174EQ38843805-B8222530-A351-4E53-BCCD-2DAB1853B46BQ39106939-B149D076-BD40-421F-A8E2-C5EEA20B9ED9Q40386747-5CA36785-F528-46AD-BB1A-49377732A38AQ41857207-E60ED4EA-B776-47D9-9F3C-2DBC06B1332EQ42292002-183A5B01-9054-4E41-BD56-C1A59677ECDFQ43043733-5FEB1C24-27DF-4086-8EED-E7688EB3D450Q47847638-D1231B3F-78D0-42AA-A0B1-642352873D35Q48162194-D987CCF4-8B75-4AB2-9CB3-0BE3ABCFAA8AQ57142083-F0DCC2DE-3788-4B77-A73B-D71CBD965941
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Daniel J Bratton
@ast
Daniel J Bratton
@en
Daniel J Bratton
@es
Daniel J Bratton
@nl
type
label
Daniel J Bratton
@ast
Daniel J Bratton
@en
Daniel J Bratton
@es
Daniel J Bratton
@nl
prefLabel
Daniel J Bratton
@ast
Daniel J Bratton
@en
Daniel J Bratton
@es
Daniel J Bratton
@nl
P106
P21
P31
P496
0000-0002-6135-0894